Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 508 participants.

Also called NCT01785849

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 508 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01785849
  • EudraCT 2012-002805-23
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Russia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01785849. Randomized; triple masking; primary purpose treatment. Start 2013-03-12 (actual); primary completion 2014-05-22 (actual). Results posted on 2017-03-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
Condition
Hyperparathyroidism, Secondary
Intervention (Drug)
Etelcalcetide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01785849
Content hash
278dc2a921ddbd01cf99c3f29cbb4ba072ed70543dad81d939a3e53769b5e270